In December 2024, nearly 20 equipment companies worldwide completed a new round of financing, with a total amount exceeding 2 billion yuan. Among them, several domestic enterprises completed financing of billions of yuan in December.

Chenxin Technology
On December 3rd, Chenxin Technology announced the completion of a 200 million yuan Series B financing, led by Guotou Chuangye, with Sunshine Ronghui and old shareholder Huoshan Stone Investment following suit. This round of financing will mainly be used for the company's forward-looking product research and development, new product mass production, and global business layout. Supplier of precision instruments and automated testing equipment for silicon carbide (SiC) power semiconductors.

Chenxin Technology was established in 2020, and its main products cover the characterization and testing of power semiconductor devices based on silicon carbide (SiC), gallium nitride (GaN), and silicon (Si). Among them, in the field of high-end medical imaging equipment, Chenxin Technology focuses on products such as dual energy transient CT high-voltage generators and X-ray sources. The CT medical high-voltage generator product, which has been invested in long-term research and development, is being imported into top tier factories and is about to complete the fixed-point and small-scale production of mainstream models.

Caldwell's
On December 5th, Kaidewei announced the completion of nearly 200 million yuan in Series B financing, led by Fir Creek Capital with a total investment of 50 million yuan, followed by Wuhan High tech, Hongtai Industry Finance, Hubei Provincial Science and Technology Investment, Jiuzhou Tongchuchang Investment and other institutions. This round of funds will be used for the clinical development and market expansion of the company's various products in the field of gynecological tumor diagnosis and treatment.

The two original in vitro diagnostic kits developed by Kaidewisi have been approved for two consecutive years to enter the National Medical Products Administration's innovative medical device review green channel. They are expected to help with rapid screening and precise diagnosis and treatment of gynecological tumors and precancerous lesions such as endometrial cancer and cervical cancer, greatly improving patient accessibility and reducing unnecessary invasive tests and medical costs.

Xi Microorganisms
On December 6th, Xi Microorganisms announced the completion of nearly 100 million yuan in Series A financing, led by Daotong Investment. This round of financing will be used to accelerate the research and development, human clinical trial research, international development registration, and marketing expansion of ophthalmic and regenerative medicine innovative products such as artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelial cells, and artificial dermis in the pipeline.

Xi Microorganisms was founded in 2020, focusing on innovative product development of new bio modified materials for ophthalmic implantable medical devices and regenerative medical devices. At present, Xi Microorganisms has built three static ISO 7 level clean production workshops (local static ISO 5 level), and according to ISO13485 FDA QSR820、 China has established a sound quality system for medical device production quality management standards.

East Coast Convergence
On December 12th, Meidong Huicheng announced the completion of hundreds of millions of yuan in C++round financing, led by Qudao Asset Management. The financing proceeds will be used for the development and operation of consumer healthcare and life science storage pipelines.

Meidong Huicheng started in Kunshan, Jiangsu in 2017 and has successfully achieved large-scale commercialization of CDMO business for minimally invasive surgical instruments. It has also rapidly expanded its business to the entire field of IVD and life sciences. At present, the product pipeline of Meidong Huicheng has expanded to the consumer medical field, which is expected to ignite a new growth curve.

Xianwei Vision
On December 13th, Xianwei Vision received an investment of over 100 million yuan. Xianwei Vision focuses on the application research of femtosecond lasers in ophthalmic surgery and biomaterial processing, with a long history in optics, optoelectronics, and laser fields.

It is reported that Xianwei Vision has research and development centers in Nanjing and Wuhan. Its first commercial product, the full femtosecond laser corneal refractive surgery device, originated from the technology transformation of the Wuhan Optoelectronics National Research Center of Huazhong University of Science and Technology. Xianwei Vision has obtained more than 10 patents, and the patents are still being continuously applied for, basically realizing the localization of the core technology and key components of the full femtosecond laser corneal refractive surgery equipment. In the last month of 2024, Xianwei Vision, which has obtained financing, is comprehensively promoting the production of 7 devices. The first batch of products will be put into use in 6 well-known ophthalmic hospitals in China before the Spring Festival next year.

Zhitong Technology
On December 16th, Zhitong Technology announced the completion of nearly 100 million yuan in Series A financing. This round of financing is jointly led by Aibo Qingshi Fund and Shanlan Capital, with Zero Venture Capital and Chongqing Airui Ling as co investors. Kaicheng Capital serves as the exclusive financial advisor for this transaction and will continue to be responsible for subsequent financing. The funds raised in this round of financing will mainly be used for the research and development, registration, and market promotion of modular products for surgery and ophthalmology, as well as complete microsurgical external mirrors.

Founded in 2020, Zhitong Technology has a strong R&D team dedicated to the research and development of key technologies for visual perception and intelligent decision-making in microsurgical surgical scenes. Focusing on the core product line direction of ultra high definition stereoscopic vision technology and intelligent human-computer interaction technology, the company has established a development strategy of "computational imaging+industry applications" and aspires to become an industry leader in fine visual imaging technology, a global provider of high-end medical imaging modules, equipment, and digital surgical solutions.

Weimai Medical
On December 17th, Weimai Medical completed a Series B financing of over 100 million yuan, invested by a well-known domestic top fund, with Kaicheng Capital serving as the exclusive financial advisor. The relevant funds will be used to expand Weimai Medical's multi line layout in the fields of energy medicine and medical devices, and accelerate the promotion of YOUMAGIC ® By expanding the production and sales channels, as well as brand building of core products, we will provide strong financial support for YOUMAGIC and Weimai Medical's research and development innovation, as well as market expansion.

It is understood that this round of financing coincides with a critical period for the strategic development of YOUMAGIC and its R&D company Weimai Medical, and also coincides with YOUMAGIC ® A good opportunity to successfully obtain the NMPA Class III Medical Device Registration Certificate. The approval of this registration certificate fully demonstrates the safety, reliability, clinical effectiveness, and rigorous testing of Weimai product technology, marking YOUMAGIC ® We have established technological barriers and competitive advantages, and fully embarked on the journey of commercialization.

Weike Medical
On December 21st, Weike Medical announced that it has successfully completed its Series C financing, with a financing amount of hundreds of millions of yuan, fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City. This round of financing will provide strong financial support for Weike Medical in product research and development, market expansion, and international strategic layout.

Since its establishment in July 2018, Weike Medical has always focused on the major clinical needs in the cardiovascular field, especially in the field of minimally invasive interventions for heart failure and structural heart disease. The company focuses on research and development, technical services, production, and sales, and is committed to building an innovative medical device platform for cardiovascular full cycle solutions, providing advanced products and treatment plans for patients and doctors worldwide.

Source: https://news.yaozh.com/archive/44761.html